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Chronic breathlessness [1] causes immense suffering in cardiorespiratory diseases. The 
functional impact of activity-related breathlessness, measured on the modified Medical 
Research (mMRC) scale [2], is highly prognostic, informs disease evaluation and 
management including in chronic obstructive pulmonary disease (COPD) [3], and is widely 
used for determining eligibility in clinical trials.
In clinical practice, mMRC is often rated by physicians based on the patient’s medical history. 
It is unknown to what extent mMRC ratings differ when administered by clinicians compared 
with patient self-report. The ratings may be influenced by other clinical characteristics, such 
as the patient’s functional status. The New York Heart Association (NYHA) scale, which is 
similar to mMRC and is key for management of heart failure, is associated with functional 
status, measured using the Australia-modified Karnofsky Performance Status (AKPS) [4], but 
discriminates poorly between clinically important performance states in people with advanced 
disease [4].
The primary aim of this study was to evaluate the agreement between clinician- and patient-
reported mMRC scores. Secondary aims were to evaluate whether the agreement differed by 
severity of activity-related breathlessness and how clinicians’ and patients’ ratings correlated 
to the patient’s functional status.
This was a pooled analysis of two randomised, placebo-controlled trials of morphine [5] and 
sertraline [6] for chronic breathlessness. Only data at screening and baseline were used 
(before any study treatment was initiated). Patients had severe life-limiting illnesses and 
chronic breathlessness defined as a clinician-rated mMRC ≥ 2 at screening despite optimal 
treatment for the underlying cause(s), as detailed elsewhere [5, 6]. Participants with missing 
data on clinician- or patient-reported mMRC (n=68) were excluded. No data were imputed.
mMRC was rated by clinicians at screening and was then self-reported by patients in their 
study diary at baseline (before randomisation). Patients’ functional status was rated by 
clinicians at baseline using AKPS [7]. The primary analysis compared clinician and patient 
mMRC ratings conducted within three days or less. A sensitivity analysis was performed 
using ratings performed four days or more apart. Agreement was analysed using quadratic-






























































weighted Cohen’s Kappa, categorized according to Landis et al. [8]: 0 = no (chance) 
agreement; 0.01-0.2 = slight; 0.21-0.40 = fair; 0.41-0.60 = moderate; 0.61-0.80 = substantial; 
≥0.81 = high agreement. Associations between the mMRC ratings and patients’ functional 
status (AKPS) were analysed using Kendall's tau. The study was approved by relevant human 
research ethics committees and all participants provided written, informed consent. Statistical 
analyses were conducted using the Statistical Package for the Social Sciences (SPSS) 
software Version 24.0 (Armonk, NY: IBM Corporation).
In total, 464 patients (294 from the morphine and 170 from the sertraline trial) had paired 
clinician and patient mMRC ratings. The time between clinician and patient mMRC ratings 
was a median 0 (IQR, -1, 0) days; 312 patients had ratings within 3 days (by 42 physicians) 
and were included in the primary analysis: mean age 73.8 (standard deviation [SD] 8.8); 
63.5% men; most common diagnoses were COPD (70.5%), interstitial lung disease (17.3%), 
lung cancer (13.8%) and heart failure (4.8%); and patients were ambulatory with a mean 
AKPS of 61.5 (SD 10.1). Characteristics were similar between patients who were included 
and excluded from the primary analysis.
Agreement between clinician- and patient-reported mMRC (scored within 3 days; n=312) is 
shown in Figure 1. The ratings differed considerably and the agreement for all categories was 
slight to fair, Cohen’s kappa 0.238 (95% confidence interval [CI] 0.143, 0.326). The rate of 
under- and over-estimation by clinicians compared to patient self-reports was similar (Figure 
1). However, agreement was better for higher mMRC scores (25% for clinician mMRC 2; 
31% for mMRC 3; and 61% for mMRC 4; p < 0.001 using Mantel–Haenszel chi‐square test). 
Functional status was more closely related to clinician-rated mMRC (tau=-0.42; p<0.001) 
than patient-rated mMRC (tau=-0.22; p<0.001). For scores more than three days apart 
(n=152), agreement was slightly lower, Cohen’s kappa 0.154 (95% CI 0.047, 0.260), but 
findings were otherwise similar.
This study for the first time evaluated the agreement between clinician- and patient-rated 
mMRC. The main finding was that only a minority of ratings agreed, with similar rates of 
clinician under- and over-estimation. These findings are consistent with reported 
disagreement between clinicians’ and patients’ ratings of subjective measures including 
symptom intensity [9] and quality of life [10]. Our study is the first indication of substantial 






























































disagreement between clinicians and patients when assessing even a relatively objective 
measure such as when breathlessness limits exertion. 
Secondly, a novel finding was that as activity-related breathlessness worsened, agreement 
between patients and their clinicians improved. The subjective symptom of breathlessness 
might be under-detected by the clinician until becomes visible as a “clinical sign” of reduced 
function. Functional status was more closely related to clinician-rated than patient-rated 
mMRC. This could reflect that patients reduce or avoid physical activities to limit their 
breathing discomfort – which could lead to patients under-estimating their activity-related 
breathlessness (as they become more inactive) – contributing to symptom under-report. 
Clinicians may also incorporate other clinical information when rating breathlessness such as 
the patient’s disease severity and functional status. In fact, this could make the clinician-
ratings even more predictive than the self-report of future clinical outcomes, which should be 
evaluated in studies with long term outcome data.
A strength of the analysis was the large sample of patients with chronic breathlessness, with 
ratings using standardised scales in the setting of randomised controlled trials. A potential 
limitation was the time between the ratings, hence the primary analysis included ratings done 
within three days. Given that mMRC only has five levels that are quite broad and the 
chronicity of breathlessness in the study population, mMRC scores should be stable within 
time periods longer than three days. As a clinician rated mMRC of 2-4 was an eligibility 
criteria, findings pertain mostly to moderate to severe chronic breathlessness. The improved 
agreement for higher mMRC scores might be partially related to getting closer to the upper 
limit of the scale. Higher agreement might also be found near the lower limit (mMRC 0-1) 
giving a U-shaped agreement for mMRC, which should be further explored. There were no 
data on how each clinician established a patient’s mMRC. Involvement of patients in the 
clinician-rating is possible but would in fact make their scores more similar and over-
estimated the agreement.  
The low agreement between clinician- and patient-rated mMRC has direct clinical 
implications, as mMRC is widely used to assess disease severity and prognosis, guide 
patients’ management, and select participants for interventional symptom trials [3, 11]. The 
findings highlight that activity-related breathlessness is a subjective experience that is only 
weakly related to other commonly measured clinical parameters (including functional status), 






























































and that symptom assessment should include self-report whenever possible to accurately 
capture patients’ experiences [1, 12]. At the same time, given the complexity of chronic 
progressive diseases, comorbidities and symptoms, assessment necessitates clinician’s 
involvement, which may also mitigate symptom under-reporting by patients. Training of 
clinicians to adequately assess breathlessness and gain a better proxy mMRC where self-
report is not possible, would give more accurate representation of patient status, which is 
important in cardiorespiratory disease. 
Improved method to assess exertional breathlessness is needed for use in clinical care, for 
selecting participants to clinical trials and to measure treatment effects. The mMRC might 
under-report symptoms in patients with milder disease and who have become less active due 
to breathlessness [13], and is too unresponsive to detect change. Standardised tests for 
measuring changes in activity-related breathlessness have been validated in COPD [14, 15].
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Chronic breathlessness [1] causes immense suffering in cardiorespiratory diseases. The 
functional impact of activity-relalted breathlessness, measured on the modified Medical 
Research (mMRC) scale [2], is highly prognostic, informs disease evaluation and 
management including in chronic obstructive pulmonary disease (COPD) [3], and is widely 
used for determining eligibility in clinical trials.
In clinical practice, mMRC is however often rated by physicians based on the patient’s 
medical history. It is unknown to what extent mMRC ratings differ when administered by 
clinicians compared with patient self-report. The ratings may be influenced by other clinical 
characteristics, such as the patient’s functional status. The New York Heart Association 
(NYHA) scale, which is similar to mMRC and is key for management of heart failure, is 
associated with functional status, measured using the Australia-modified Karnofsky 
Performance Status (AKPS) [4], but discriminates poorly between clinically important 
performance states in people with advanced disease [4].
The primary aim of this study was to evaluate the agreement between clinician- and patient-
reported mMRC scores. Secondary aims were to evaluate whether the agreement differed by 
severity of activity-relatedthe breathlessness and how clinicians’ and patients’ ratings 
correlated to the patient’s functional status.
This was a pooled analysis of two randomised, placebo-controlled trials of morphine [5] and 
sertraline [6] for chronic breathlessness. Only data at screening and baseline were used 
(before any study treatment was initiated). Patients had severe life-limiting illnessesdisease 
and chronic breathlessness defined as a clinician-rated mMRC ≥ 2 at screening despite 
optimal treatment for the underlying cause(s), as detailed elsewhere [5, 6]. Participants with 
missing data on clinician- or patient-reported mMRC (n=68) were excluded. No data were 
imputed.
mMRC was rated by clinicians at screening and was then self-reported by patients in their 
study diary at baseline (before randomiszation). Patients’ functional status was rated by 
clinicians at baseline using AKPS [7]. The primary analysis compared clinician and patient 
mMRC ratings conducted within three days or less. A sensitivity analysis was performed 






























































using ratings performed four days or more apart. Agreement was analysed using quadratic-
weighted Cohen’s Kappa, categorized according to Landis et al. [8]: 0 = no (chance) 
agreement; 0.01-0.2 = slight; 0.21-0.40 = fair; 0.41-0.60 = moderate; 0.61-0.80 = substantial; 
≥0.81 = high agreement. Associations between the mMRC ratings and patients’ functional 
status (AKPS) were analysed using Kendall's tau. The study was approved by relevant human 
research ethics committees and all participants provided written, informed consent. Statistical 
analyses were conducted using the Statistical Package for the Social Sciences (SPSS) 
software Version 24.0 (Armonk, NY: IBM Corporation).
In total, 464 patients (294 from the morphine and 170 from the sertraline trial) had paired 
clinician and patient mMRC ratings. The time between clinician and patient mMRC ratings 
was a median 0 (IQR, -1, 0) days; 312 patients had ratings within 3 days (by 42 physicians) 
and were included in the primary analysis: mean age 73.8 (standard deviation [SD] 8.8); 
63.5% men; most common diagnoses were COPD (70.5%), interstitial lung disease (17.3%), 
lung cancer (13.8%) and heart failure (4.8%); and patients were ambulatory with a mean 
AKPS of 61.5 (SD 10.1). Characteristics were similar between patients who were included 
and excluded from the primary analysis.
Agreement between clinician- and patient-reported mMRC (scored within 3 days; n=312) is 
shown in Figure 1. The ratings differed considerably and the agreement for all categories was 
slight to fair, Cohen’s kappa 0.238 (95% confidence interval [CI] 0.143, 0.326). The rate of 
under- and over-estimation by clinicians compared to patient self-reports was similar (Figure 
1). However, agreement was better for higher mMRC more severe breathlessness scores (25% 
for clinician mMRC 2; 31% for mMRC 3; and 61% for mMRC 4; p < 0.001 using Mantel–
Haenszel chi‐square test). The patient’s fFunctional status was more closely related to the 
clinician-rated mMRC (tau=-0.42; p<0.001) than to the patient-rated mMRC (tau=-0.22; 
p<0.001). For scores more than three days apart (n=152), agreement was slightly lower, 
Cohen’s kappa 0.154 (95% CI 0.047, 0.260), but findings were otherwise similar.
This study for the first time evaluated the agreement between clinician- and patient-rated 
mMRC. The main finding was that only a minority of ratings agreed, with similar rates of 
clinician under- and over-estimation. These findings are consistent with reported 
disagreement between clinicians’ and patients’ ratings of subjective measures including 
symptom intensity [9] and quality of life [10]. Our study is the first indication of substantial 






























































disagreement between clinicians and patients when assessing even a relatively objective 
measure such as when breathlessness limits exertion. 
Secondly, a novel finding was that as activity-related chronic breathlessness worsened, 
agreement between patients and their clinicians improved. The subjective symptom of 
breathlessness might be under-detected by the clinician until becomes visible as a “clinical 
sign” of reduced function.  The clinician-rated Functional status was more closely related to 
clinician-rated than patient-rated mMRC was more strongly related to the patient’s functional 
status than did the patients’ self-rated breathlessness. This could reflect that patients reduce or 
avoid physical activities to limit their breathing discomfortdistress from breathlessness – 
which could lead to patients under-estimating their functional capacity or activity-related 
breathlessness (as they become more inactive) – contributing to symptom under-report. 
Clinicians may also incorporate other clinical information when rating breathlessness such as 
the patient’s disease severity and functional status. In fact, this could make the clinician-
ratings even more predictive than the self-report of future clinical outcomes, which should be 
evaluated in studies with long term outcome data.
A strength of the analysis was the large sample of patients with chronic breathlessness, with 
ratings using standardised scales in the setting of randomised controlled trials. A potential 
limitation was the time between the ratings, hence the primary analysis included ratings done 
within three days. Given that mMRC only has five levels that are quite broad and the 
chronicity of breathlessness in the study population, mMRC scores should be stable within 
time periods longer than three days. As a clinician rated mMRC of 2-4 was an eligibility 
criteria, findings pertain mostly to moderate to severe chronic breathlessness. The improved 
agreement for higher mMRC scores might be partially related to getting closer to the upper 
limit of the scale. Higher agreement might also be found near the lower limit (mMRC 0-1) 
giving an U-shaped agreement for mMRC, which should be further explored. There were no 
data on how each clinician established a patient’s mMRC. Involvement of patients int the 
clinician-rating is possible but would in fact make their scores more similar and over-
estimated the agreement.  
The low agreement between clinician- and patient-rated mMRC has direct clinical 
implications, as mMRC is widely used to assess disease severity and prognosis, to guide 






























































patients’ management, and to select participants to for interventional symptom trials [3, 11]. 
The findings highlight that activity-related breathlessness is a subjective experience that is 
only weakly related to other commonly measured clinical parameters (including functional 
status), and that symptom assessment should include self-report whenever possible to 
accurately capture patients’ experiences [1, 12]. At the same time, given the complexity of 
chronic progressive diseases, comorbidities and symptoms, assessment necessitates clinician’s 
involvement, which may. This could also mitigate any symptom under-reporting by patients. 
Training of clinicians to adequately assess breathlessness and gain a better proxy mMRC 
where self-report is not possible, would give more accurate representation of patient status, 
which is important in cardiorespiratory disease. 
Improved method is needed to assess exertional breathlessness is needed for use in clinical 
care, for selecting participants to clinical trials and to measure treatment effects. Research is 
needed on how to further improve the assessment of activity-related breathlessness. The 
mMRC might under-report symptoms in patients with milder disease and who have become 
less active due to breathlessness [13], and is too unresponsive to detect change. Standardiszed 
tests for measuringdetecting changes in exertional activity-related breathlessness have been 
validated in COPD [14, 15].
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